DEF 14A: Lucid Diagnostics Reschedules Annual Meeting, Proposes Stock Issuance Approval and Increase in Authorized Shares

Lucid Diagnostics has rescheduled its annual meeting to July 23, 2024, to modify proposals including stock issuance approval and an increase in authorized common stock.

Summary

• Lucid Diagnostics has rescheduled its annual meeting of stockholders to July 23, 2024, to modify the proposals to be voted upon.
• The meeting will be held virtually at 11:00 a.m. Eastern time.
• Stockholders of record as of May 29, 2024, are entitled to vote.
• The proposals include the election of three Class C directors, approval of common stock issuance under Series B and B-1 Preferred Stock, an amendment to increase authorized common stock by 100,000,000 shares (from 200,000,000 to 300,000,000), and ratification of Marcum LLP as the independent accounting firm for 2024.
• The Board recommends voting FOR all proposals.
• PAVmed Inc., holding approximately 56.4% of the voting power, intends to vote in favor of the director nominees, stock issuance, and accountant ratification.
• The company is seeking stockholder approval for the issuance of shares of common stock related to the Series B and Series B-1 Preferred Stock offerings, as required by Nasdaq rules.
• The company is also seeking approval to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000 to provide flexibility for future business needs.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focusing on procedural matters related to the annual meeting and required approvals. The potential dilution and anti-takeover implications temper any positive sentiment.

Positives

• The company is taking steps to ensure it can meet its obligations under outstanding options, warrants, and convertible securities.
• Increasing the authorized shares provides flexibility to respond to future business needs and opportunities, such as additional equity awards, financing, acquisitions, or strategic partnerships.
• The company has a strong controlling shareholder in PAVmed, which intends to vote in favor of the management proposals.

Negatives

• Failure to approve the stock issuance proposal will prevent the company from issuing shares in excess of 19.99% of outstanding shares, potentially impacting its ability to raise capital.
• The issuance of additional shares of common stock may have a dilutive effect on earnings per share and on the equity and voting power of existing security holders.
• The additional shares of common stock could be used by management to oppose a hostile takeover attempt or to delay or prevent changes in control or management of the company.

Risks

• Failure to obtain stockholder approval for the stock issuance proposal could negatively impact the company's ability to raise capital in the future.
• The issuance of additional shares may dilute existing stockholders' ownership and potentially decrease the market price of the common stock.
• The controlling interest of PAVmed may discourage a change of control that other holders of the company's stock may favor.

Future Outlook

The company intends to hold its 2025 annual meeting of stockholders on June 25, 2025.

Industry Context

The company's need to seek approval for stock issuance is common in the biotech industry, where raising capital is essential for funding research, development, and commercialization efforts. The proposed increase in authorized shares reflects a proactive approach to ensure the company has the necessary resources to pursue its strategic goals.

Comparison to Industry Standards

• Companies like Exact Sciences (EXAS) and Hologic (HOLX) have successfully utilized early detection diagnostics, similar to Lucid Diagnostics' focus with EsoGuard and EsoCheck.
• The reliance on preferred stock financing is a common strategy among growth-stage biotech companies, comparable to companies like Citius Pharmaceuticals (CTXR) and DarioHealth (DRIO), where Lucid Diagnostics' CFO, Dennis McGrath, also serves as a director.
• The management services agreement with PAVmed is a unique arrangement, but shared services models are often seen in parent-subsidiary relationships to optimize costs and resources.

Related Party Transactions

• The company has a management services agreement with PAVmed, paying approximately $9.0 million and $5.6 million in the years ended December 31, 2023 and 2022, respectively.
• The company has a payroll and benefit expense reimbursement agreement with PAVmed, incurring approximately $1.8 million and $10.2 million in the years ended December 31, 2023 and 2022, respectively.
• The company entered into a license agreement with PAVmed for certain intellectual property rights relating to esophageal ablation technology.
• The company acquired CapNostics, LLC from PAVmed Subsidiary Corp. in exchange for shares of the company's common stock.

Stakeholder Impact

• Approval of the stock issuance proposal will allow the company to continue to raise capital, which could benefit shareholders in the long term.
• Failure to approve the stock issuance proposal could limit the company's ability to raise capital, potentially impacting its ability to execute its business plan.
• The issuance of additional shares may dilute existing stockholders' ownership and potentially decrease the market price of the common stock.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will file the certificate of amendment with the Delaware Secretary of State if the Authorized Capital Proposal is approved.
• The company will continue to seek stockholder approval of the Stock Issuance Proposal until it obtains such approval.

Key Dates

Keywords

annual meeting, proxy statement, stock issuance, authorized shares, board of directors, Lucid Diagnostics, PAVmed, Series B Preferred Stock, Series B-1 Preferred Stock, Marcum LLP